Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ADH1B | P00325 | 1/20 | 0.31 |
| ▸ | ADH1C | P00326 | 1/20 | 0.31 |
| ▸ | ADH1A | P07327 | 1/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | ADH7 | P40394 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747287 | 1.00 | SIGMAR1 (0.44) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL23082604 | 0.95 | EPHX1 (0.42) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL26046825 | 0.93 | SIGMAR1 (0.43) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL11491450 | 0.90 | LMNA (0.42) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL21799677 | 0.89 | DNM1 (0.41) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL21799765 | 0.89 | DNM1 (0.41) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL21799463 | 0.89 | DNM1 (0.41) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL21800094 | 0.89 | DNM1 (0.41) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL21800100 | 0.89 | DNM1 (0.41) | SIGMAR1LMNACNR1ADRA1ATDP1 | |
| SCHEMBL21799697 | 0.89 | DNM1 (0.41) | SIGMAR1LMNACNR1ADRA1ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | claimed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | claimed |
| WO-2011123241-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2011-10-06 | — | — | WO | claimed |
| US-20240376246-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2024-11-14 | — | — | US | disclosed |
| EP-4402191-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2024-07-24 | — | — | EP | disclosed |
| WO-2023041443-A1 | ONE-POT PROCESS FOR THE PRODUCTION OF POLYCARBODIIMIDE CURED POLYMERS | BASF SE (DE) | 2023-03-23 | — | — | WO | disclosed |
| EP-2552990-B1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-20140373918-A1 | PHOTOVOL TAlC MODULES AND METHODS OF MAKING THE SAME | PPG INDUSTRIES OHIO, INC. | 2014-12-25 | — | — | US | disclosed |
| EP-2552990-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | Dow Global Technologies LLC (US) | 2013-02-06 | — | — | EP | disclosed |
| US-20130018147-A1 | POLYURETHANE/POLYUREA SPRAY ELASTOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2013-01-17 | — | — | US | disclosed |
| WO-2013009372-A1 | PHOSPHORUS-CONTAINING SECONDARY AMINE COMPOUNDS | HUNTSMAN PETROCHEMICAL LLC (US) | 2013-01-17 | — | — | WO | disclosed |
| WO-2008112636-A1 | CHAIN EXTENDERS | ALBEMARLE CORPORATION (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080194788-A1 | Diimines and Secondary Diamines | ALBEMARLE CORPORATION (US) | 2008-08-14 | — | — | US | disclosed |
| WO-2008086437-A1 | FORMULATIONS FOR REACTION INJECTION MOLDING AND FOR SPRAY SYSTEMS | ALBEMARLE CORPORATION (US) | 2008-07-17 | — | — | WO | disclosed |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | ALBEMARLE CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070270566-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-7288677-B2 | Diimines and secondary diamines | ALBEMARLE CORPORATION (US) | 2007-10-30 | — | — | US | disclosed |
| US-20070073030-A1 | Chain Extenders | ALBEMARLE CORPORATION (US) | 2007-03-29 | — | — | US | disclosed |
| US-20060217567-A1 | Diimines and secondary diamines | ALBEMARLE CORPORATION | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004406-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | SIGMAR1 1296/4885LMNA 3166/4885CNR1 978/4885 |
| US-20070270566-A1 | Chain Extenders | DDC, PARG, ODC1 | SIGMAR1 1071/4885LMNA 654/4885CNR1 2843/4885 |
| US-20080033210-A1 | DIIMINES AND SECONDARY DIAMINES | DDT, DDC, AOC1 | SIGMAR1 1296/4885LMNA 3166/4885CNR1 978/4885 |
| US-20080194788-A1 | Diimines and Secondary Diamines | DDT, DDC, AOC1 | SIGMAR1 1244/4885LMNA 3427/4885CNR1 525/4885 |
| US-20060217567-A1 | Diimines and secondary diamines | DDT, DDC, AOC1 | SIGMAR1 1296/4885LMNA 3166/4885CNR1 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.